Marginal ulcer

Revision as of 05:35, 17 March 2026 by Ostermayer (talk | contribs) (Created page with "'''Marginal ulcer''' (also called stomal ulcer or anastomotic ulcer) is a mucosal ulceration that develops at or near a surgical gastroenteric anastomosis, most commonly on the jejunal side of the gastrojejunostomy after Roux-en-Y gastric bypass (RYGB).<ref>Coblijn UK, Goucham AB, Lagarde SM, Kuiken SD, van Wagensveld BA. Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review. ''Obes Surg''....")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Marginal ulcer (also called stomal ulcer or anastomotic ulcer) is a mucosal ulceration that develops at or near a surgical gastroenteric anastomosis, most commonly on the jejunal side of the gastrojejunostomy after Roux-en-Y gastric bypass (RYGB).[1] It is the most common late complication of RYGB and may present to the emergency department with pain, GI bleeding, or perforation.

Background

  • Incidence ranges from 0.6% to 25% following RYGB, with a mean prevalence of approximately 4.6%[2]
  • Typically presents a median of 1-2 years after surgery, but can occur from weeks to >10 years postoperatively
  • Ulcers are located on the anastomosis (~50%) or the jejunal mucosa (~40%)
  • Pathophysiology is multifactorial:
    • Acid exposure — jejunal mucosa lacks protective buffering mechanisms against gastric acid
    • Ischemia — tension on the anastomosis, compromised local blood supply
    • Large gastric pouch — greater parietal cell mass increases acid production[3]
    • Foreign body reaction — non-absorbable suture material or exposed staples at the anastomosis
    • Gastrogastric fistula — allows acid from the excluded gastric remnant to reach the pouch
  • Risk factors (by meta-analysis):[4]

Clinical Features

  • Epigastric or periumbilical pain (most common, ~63%)[5]
  • Nausea and vomiting
  • Reduced oral intake / early satiety
  • GI bleeding (~24%)
  • Dysphagia (if associated anastomotic stricture)
  • Complicated presentations:
    • Perforation — acute-onset severe abdominal pain, peritoneal signs, sepsis
      • May present with left shoulder pain (diaphragmatic irritation)
    • Hemorrhagehemodynamic instability, hematemesis, hematochezia
    • Stricture — progressive dysphagia, vomiting, inability to tolerate oral intake
    • Gastrogastric fistula — chronic symptoms, weight regain
  • Up to 28% of patients may be asymptomatic (discovered incidentally on surveillance endoscopy)

Differential Diagnosis

Diffuse Abdominal pain

Evaluation

Workup

  • Labs:
    • CBC — anemia (chronic blood loss), leukocytosis (perforation/infection)
    • BMP — electrolyte abnormalities from vomiting or poor oral intake
    • Lipase — rule out pancreatitis
    • Lactate — if concern for perforation or ischemia
    • Type and screen — if GI bleeding
    • H. pylori testing (stool antigen or urea breath test preferred over serology post-bypass)
    • Iron studies — if chronic anemia
  • Imaging:
    • CT abdomen/pelvis with IV contrast — study of choice in the ED for suspected complications[6]
      • May show: wall thickening at the gastrojejunostomy, periananastomotic fat stranding, extraluminal air (perforation), extraluminal fluid, oral contrast leak
      • CT also evaluates for internal hernia, small bowel obstruction, and abscess
    • Upright CXR or left lateral decubitus — may show free air under diaphragm if perforation
    • UGI fluoroscopy with water-soluble contrast — can confirm contained perforation vs free leak
  • EGD (esophagogastroduodenoscopy):
    • Gold standard for diagnosis
    • Directly visualizes ulcer at or near gastrojejunostomy
    • Evaluates for exposed suture/staple material, gastrogastric fistula, stricture
    • Allows biopsy (rule out malignancy, test for H. pylori)
    • Enables therapeutic intervention (hemostasis, dilation)
    • May not be immediately available in the ED setting

Diagnosis

  • Suspect in any post-bariatric surgery patient presenting with epigastric pain, GI bleeding, or signs of perforation
  • Definitive diagnosis by EGD with direct visualization of ulcer at the gastrojejunal anastomosis
  • CT findings suggestive but not diagnostic; primarily used to identify complications (perforation, abscess, obstruction)
  • Visible suture material or staples at the ulcer base is a characteristic finding

Management

Medical management (uncomplicated)

  • Proton pump inhibitor (PPI) — mainstay of treatment[7]
    • High-dose PPI (e.g., omeprazole 40 mg BID or pantoprazole 40 mg BID)
    • Duration: minimum 8-12 weeks; many patients require long-term or indefinite PPI
  • Sucralfate 1 g QID (mucosal protectant, adjunct to PPI)
  • Risk factor modification:
    • Smoking cessation (critical)
    • Discontinue NSAIDs, aspirin (if possible; discuss with prescribing physician)
    • Limit alcohol
    • H. pylori eradication if positive[8]
    • Optimize glycemic control in diabetics
    • Discontinue or minimize corticosteroids
  • Endoscopic removal of exposed foreign material (sutures, staples) if identified

GI bleeding

  • Standard approach to Upper GI bleed
  • Aggressive resuscitation, blood transfusion as needed
  • IV PPI (e.g., pantoprazole 80 mg bolus then 8 mg/hr drip)
  • Urgent EGD for diagnosis and hemostasis (clips, epinephrine injection, thermal therapy)
  • Consult surgery if hemodynamically unstable or endoscopy fails to achieve hemostasis
  • See Upper GI bleed

Perforation

  • Surgical emergency in most cases
  • NPO, IV fluid resuscitation, broad-spectrum antibiotics
  • IV PPI
  • Surgical options:[9]
    • Omental (Graham) patch repair — most common initial approach
    • Anastomotic revision with resection of ulcer bed
    • Gastric bypass reversal (complex, reserved for refractory cases)
  • Laparoscopic approach preferred if patient is hemodynamically stable and presents within 24 hours
  • Contained perforation in select hemodynamically stable patients with minimal symptoms may be considered for non-operative management with NPO, IV antibiotics, and IV PPI (emerging evidence)[10]

Stricture

  • Endoscopic balloon dilation (may require serial dilations)
  • Continue PPI therapy
  • Surgical revision if refractory

Disposition

  • Admit if:
    • Signs of perforation or peritonitis → emergent surgical consultation
    • Hemodynamically significant GI bleeding
    • Inability to tolerate oral intake
    • Severe pain requiring IV analgesia
    • Concern for sepsis or abscess
  • Discharge may be appropriate if:
    • Mild symptoms with stable vital signs
    • Tolerating oral intake
    • Reliable follow-up arranged (PPI prescription, outpatient EGD referral, bariatric surgery follow-up)
    • Clear return precautions given: worsening pain, vomiting, bloody or tarry stools, fever, lightheadedness
  • Recurrence rate is high (~30% or more), especially if risk factors are not addressed[11]
  • Approximately 9% of patients ultimately require surgical revision despite medical therapy
  • Endoscopic surveillance is recommended given high recurrence rate

See Also

External Links

References

  1. Coblijn UK, Goucham AB, Lagarde SM, Kuiken SD, van Wagensveld BA. Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review. Obes Surg. 2014;24(2):299-309.
  2. Azagury DE, Abu Dayyeh BK, Greenwalt IT, Thompson CC. Marginal ulceration after Roux-en-Y gastric bypass surgery: characteristics, risk factors, treatment, and outcomes. Endoscopy. 2011;43(11):950-954.
  3. Edholm D, Ottosson J, Sundbom M. Importance of pouch size in laparoscopic Roux-en-Y gastric bypass: a cohort study of 14,168 patients. Surg Endosc. 2016;30(5):2011-2015.
  4. Liang Y, Wang C, Yang L, et al. Nonsurgical risk factors for marginal ulcer following Roux-en-Y gastric bypass for obesity: a systematic review and meta-analysis of 14 cohort studies. Int J Surg. 2024;110(3):1793-1799.
  5. Azagury DE, Abu Dayyeh BK, Greenwalt IT, Thompson CC. Marginal ulceration after Roux-en-Y gastric bypass surgery: characteristics, risk factors, treatment, and outcomes. Endoscopy. 2011;43(11):950-954.
  6. Meissnitzer MW, Stättner S, Gmeiner D, et al. Imaging features of marginal ulcers on multidetector CT. Clin Radiol. 2023;78(2):e178-e185.
  7. Pyke O, Yang J, Cohn T, et al. Marginal ulcer continues to be a major source of morbidity over time following gastric bypass. Surg Endosc. 2019;33(10):3451-3456.
  8. Schulman AR, Abougergi MS, Thompson CC. H. pylori as a predictor of marginal ulceration: a nationwide analysis. Obesity (Silver Spring). 2017;25(3):522-526.
  9. Wendling MR, Linn JG, Keplinger KM, et al. Omental patch repair effectively treats perforated marginal ulcer following Roux-en-Y gastric bypass. Surg Endosc. 2013;27(2):384-389.
  10. Pope R, English W, Walden RL, et al. Non-operative approach to contained perforated marginal ulcers: a systematic review and case series. Am Surg. 2024;90(3):471-477.
  11. Coblijn UK, Lagarde SM, de Castro SM, Kuiken SD, van Wagensveld BA. Symptomatic marginal ulcer disease after Roux-en-Y gastric bypass: incidence, risk factors and management. Obes Surg. 2015;25(5):805-811.